Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA denies priority review for Cervarix

Executive Summary

GlaxoSmithKline's BLA for Cervarix gets 10-month standard review, setting a January 2008 user fee date for the human papilloma virus vaccine, which was submitted March 29. The decision gives Merck additional time to establish Gardasil, which began sales in June 2006, as the only vaccine on the market to prevent human papilloma virus infection and associated diseases, such as cervical cancer. GSK hopes to position Cervarix as a superior product; a head-to-head trial comparing Cervarix to Gardasil is ongoing (1"The Pink Sheet" April 2, 2007, In Brief)...

You may also be interested in...

GSK files Cervarix BLA

GlaxoSmithKline requests a priority review of its human papillomavirus vaccine Cervarix BLA, filed March 29. The submission is based on data from clinical trials in almost 30,000 females ages 10 to 55; one trial showed that Cervarix induced high antibody levels and more robust immune memory response when formulated with its proprietary AS04 adjuvant system, aluminum hydroxide plus MPL (monophosphoryl lipid A), than with aluminum hydroxide alone. GSK is looking to position Cervarix as superior to Merck's HPV vaccine Gardasil, which is formulated with aluminum hydroxide. Gardasil has been on the market since June (1"The Pink Sheet" June 12, 2006, p. 3)...

Execs On The Move: Promotions At Intuitive

Intuitive has appointed new chief financial, commercial and strategy and growth officers.

Do Fast Track Regulatory Pathways Mean Quicker Reimbursement For Gene Therapies?

The norms on securing market access are being rewritten for cell and gene therapies.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts